title: Does the Progestogen Used in Combined Hormonal Contraception Affect Venous Thrombosis Risk?
abstract: Combined hormonal contraceptives (CHCs) use a combination of estrogen and progestogen to provide contraception. The most important risk of using CHCs is venous thromboembolism (VTE). It is unclear whether the type of progestogen used in a method augments that risk. Although the evidence supporting an increase in thrombosis risk is not conclusive, neither is the evidence supporting the benefit of newer progestogens in terms of tolerability or continuation. The benefits of CHCs outweigh the risks and the absolute risk of VTE remains small. A balanced discussion of potential risks and benefits of particular CHC formulations is warranted during contraception counseling.
authors.affiliation: Department of Obstetrics and Gynecology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA. Electronic address: hanl@ohsu.edu.
authors.forename: Leo
authors.initials: L
authors.lastname: Han
authors.affiliation: Department of Obstetrics and Gynecology, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.
authors.forename: Jeffrey T
authors.initials: JT
authors.lastname: Jensen
mesh_terms: D000328:Adult; D000736:Androstenes / Q000008:administration & dosage / Q000009:adverse effects; D015897:Comorbidity; D003278:Contraceptives, Oral, Hormonal / Q000008:administration & dosage* / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007436:Intrauterine Devices, Medicated / Q000009:adverse effects; D008487:Medical History Taking; D018579:Patient Selection; D011372:Progestins / Q000008:administration & dosage* / Q000009:adverse effects*; D018570:Risk Assessment; D012307:Risk Factors; D014481:United States; D054556:Venous Thromboembolism / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control
chemical_list: D000736:Androstenes; D003278:Contraceptives, Oral, Hormonal; D011372:Progestins; C035144:drospirenone
keywords: Drospirenone; Oral contraceptive; Progestin; Progestogen; Venous thromboembolism